Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05919758 Recruiting - Neoplasms Clinical Trials

Value of Right-sided Hemicolectomy for Chldren With High-risk Neuroendocrine Tumors of the Appendix

NETkids
Start date: May 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children. .

NCT ID: NCT05919537 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Start date: September 6, 2023
Phase: Phase 1
Study type: Interventional

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

NCT ID: NCT05919264 Recruiting - Cancer Clinical Trials

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Start date: May 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.

NCT ID: NCT05918549 Recruiting - Clinical trials for Motion Analysis in Musculoskeletal Oncology

Movement Analysis in Musculoskeletal Oncology: a Pilot Study

AnMov
Start date: September 28, 2022
Phase:
Study type: Observational

Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques

NCT ID: NCT05918536 Recruiting - Neoplasms Clinical Trials

Orthopedic Oncology Surgery: Navigation, Intraoperative Imaging and Virtual Reality

Start date: May 17, 2022
Phase:
Study type: Observational

Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT

NCT ID: NCT05918445 Recruiting - Malignant Neoplasm Clinical Trials

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Start date: March 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.

NCT ID: NCT05918302 Recruiting - Clinical trials for Neuroendocrine Tumors

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

LEVEL
Start date: October 27, 2023
Phase: Phase 3
Study type: Interventional

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

NCT ID: NCT05916248 Recruiting - Clinical trials for Advanced Solid Tumor

Personalized Tumor Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

Start date: May 18, 2023
Phase: Phase 1
Study type: Interventional

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of advanced solid tumors. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

NCT ID: NCT05914974 Recruiting - Ovarian Cancer Clinical Trials

Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies

Start date: September 11, 2023
Phase:
Study type: Observational

ICK-Gyn is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in advanced or metastatic gynecological malignancies under immune checkpoint inhibitor (ICI) therapy on the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT05914545 Recruiting - Clinical trials for Advanced and Metastatic Solid Tumor

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

Start date: June 12, 2023
Phase: Phase 1
Study type: Interventional

This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.